PharmaCyte Biotech, Inc.: Form 10-Q/A for the period ended Jul 31, 2011
Filed with the SEC on Sep 20, 2011 and accepted by EDGAR at Sep 20, 2011, 16:37 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-05-01 to 2011-07-31 | $19.8k | us-gaap:Revenues |
| Cost of revenue | 3 months2011-05-01 to 2011-07-31 | $15.7k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2011-05-01 to 2011-07-31 | $4.1k | us-gaap:GrossProfit |
| Interest expense | 3 months2011-05-01 to 2011-07-31 | −$33.4k | us-gaap:InterestExpense |
| Net income | 3 months2011-05-01 to 2011-07-31 | −$686.0k | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2011-05-01 to 2011-07-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2011-05-01 to 2011-07-31 | −$119.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2011-07-31 | $83.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-07-31 | $449.2k | us-gaap:AssetsCurrent |
| Total assets | At period end2011-07-31 | $1.6m | us-gaap:Assets |
| Current liabilities | At period end2011-07-31 | $3.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-07-31 | $3.4m | us-gaap:Liabilities |
| Short-term borrowings | At period end2011-07-31 | $2.4m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2011-07-31 | −$2.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001262463-11-000192. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.